...
首页> 外文期刊>Journal of nephrology. >mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience
【24h】

mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience

机译:mTOR抑制剂用于包裹性腹膜硬化的移植后医学治疗:有利的单中心经验

获取原文
获取原文并翻译 | 示例

摘要

Encapsulating peritoneal sclerosis (EPS) is a serious complication in patients on peritoneal dialysis (PD) causing intestinal obstruction. Two different forms of EPS are reported: the classical one observed in patients on PD, and post-transplantation EPS (PostTx-EPS). The first-line therapy of classical and PostTx-EPS remains surgical treatment, but for both the complication rate and mortality are high. Recently, a few cases of EPS were successfully treated with inhibitors of mammalian target of rapamycin (mTORi). The aim of this study was to evaluate PostTx-EPS outcome in our patients, focusing on the potential benefit of mTORi treatment.
机译:进行腹膜透析(PD)引起肠梗阻的患者,封装腹膜硬化(EPS)是一种严重的并发症。报道了两种不同形式的EPS:在PD患者中观察到的经典形式,以及移植后EPS(PostTx-EPS)。经典疗法和PostTx-EPS的一线治疗仍为手术治疗,但并发症发生率和死亡率均很高。最近,用哺乳动物雷帕霉素靶标(mTORi)抑制剂成功治疗了几例EPS。本研究的目的是评估我们患者的PostTx-EPS结果,重点是mTORi治疗的潜在益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号